Pivotal readout

Bayer reports Chinese subgroup data for asundexian in stroke prevention

Adding asundexian to antiplatelet therapy cut recurrent ischemic stroke by 32% among Chinese patients in the phase 3 OCEANIC-STROKE trial, with no rise in major bleeding. The global study of more than 12,000 patients showed a 26% reduction. Bayer said the Chinese findings match the overall results and that the drug is approved in China.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Schematic animation of clotting proteins in a blood vessel, factor XI switched on to factor XIa and feeding clot growth, and the small molecule asundexian binding factor XIa's active centre while a separate bleeding-control pathway keeps running.
Asundexian: blocking factor XIa in the clotting chain. Watch the mechanism animation on the asundexian page.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call